Mood Disorders

Here are 10 things to consider when treating a patient with mood disorders.

Bipolar disorder is both underdiagnosed and overdiagnosed—though missing the diagnosis is more common. Check out this update from David N. Osser, MD.

Check out these top 10 best practices for treating patients with mood disorders.

The presentation of catatonia can vary, making its management challenging, particularly in resource-limited settings in South Africa.

A systematic review and meta-analysis showed moderate-quality evidence supporting lithium’s ability to lower mortality rates.

Learn more about a specific subset of mood disorders.

A new collaboration to address sleep disturbances associated with cognitive impairment, an unmet need.

A refined rTMS protocol, the Stanford Accelerated Intelligent Neuromodulation Therapy for major depressive disorder, shows promise in bipolar disorder.

The context and timing of symptoms is critical for a timely and accurate bipolar diagnosis.

SSRI and SNRI antidepressants were deemed the safest classes of antidepressants in the event of excess dosing in an assessment of 14 antidepressants prescribed in the United States on 3 safety indices.

Studies report an increased risk for suicidal thoughts, suicide attempts, and even death by suicide following brain injury.

Perinatal mood and anxiety disorders affect 1 in 5 of perinatal individuals who are pregnant or up to 1 year postpartum. Over the past 2 decades, the US has seen an alarming rise in these disorders.

Research shows an increased risk for suicidal thoughts, suicide attempts, and even death by suicide following brain injury.

The weight-adjusted waist index was a stronger predictor of depressive symptoms than either body mass index or waist circumference.

Review tapering challenges and strategies for benzodiazepines in this Special Report article.

The latest in mood disorder news, all in one place.

Antidepressants are differentiated by long-term response in a 2-year cohort study of patients with MDD.

“The selectivity of NBI-1070770 for the NMDA NR2B receptor may benefit patients with moderate to severe depression.”

The experts weighed in on a wide variety of psychiatric issues for the March 2024 issue of Psychiatric Times.

From a promising new intervention for treatment-resistant depression to another look at the STAR*D controversy, here are highlights from the week in Psychiatric Times.

Our Mood Disorders Section Editor discusses the disorder in honor of World Bipolar Day.

What is new in research on bipolar disorder?

Here’s a look back at selections from our March content series on mood disorders.

This treatment is now the first and only TMS treatment that is FDA-cleared for this patient population.

What is the Clubhouse model of psychosocial rehabilitation, and how can it benefit both patients and clinicians alike?

“Our patients, our field, and our integrity demand a better explanation of what happened in STAR*D than what has thus been provided.”

In this CME article, review the principles and applications of both invasive and noninvasive neuromodulation techniques for the treatment of mood disorders.

Here's how embracing a comprehensive, patient-centered approach and staying informed about emerging treatments can help mental health professionals make a difference in the lives of patients with TRD.

The Psychiatric Times Special Report on Treatment-Resistant Depression includes expert discussions on how clinicians can manage major depressive disorder and treatment-resistant depression in patients who do not achieve wellness right away.

Take a look back at our recent coverage relating to our March content theme.